论文部分内容阅读
目的对于参芪花粉片联合化疗对于小细胞肺癌与非小细胞肺癌治疗的预后比较分析。方法研究选取2014—2016年间就诊的确诊肺癌患者76例,分为参芪花粉片联合化疗治疗的观察组和仅使用化疗治疗的对照组进行研究分析。随访收集患者疗效以及预后信息,本研究主要分析讨论了随访3个月的短期预后情况,并进行比较讨论。统计分析使用SPSS 16.0统计软件包。结果 NSCLC患者中观察组的完全缓解率为3.33%,对照组未见完全缓解患者;与对照组比较,观察组的稳定病例比例高于对照组,观察组的进展病例所占比例显著低于对照组,P<0.01;此外两组总有效率比较也提示观察组高于对照组P<0.01。小细胞肺癌患者中观察组和对照组随访3个月的疗效情况与非小细胞肺癌患者相似。NSCLC患者的预后情况分析结果提示观察组的生活质量改善的比例为59.09%,高于对照组的45.45%,P<0.05;生活质量降低的比例则表现出低于对照组P<0.01;观察组3个月随访的复发率为4.55%,显著低于对照组,P<0.01。在小细胞肺癌患者中观察组的生活质量改善的比例高于对照组,P<0.01;而稳定的比例低于对照组,P<0.05。观察组3个月随访的转移率为12.50%,显著低于对照组,P<0.05。结论参芪花粉片联合化疗对于NSCLC和小细胞肺癌患者的短期预后生活质量改善均起到很好效果,特别是对于NSCLC患者更为明显;此外参芪花粉片联合化疗可以在一定程度上减低NSCLC患者复发率和小细胞肺癌患者的转移率。
Objective To compare the prognosis of small cell lung cancer and non-small cell lung cancer treated with shenqi pollen tablets combined with chemotherapy. Methods Sixty-six patients diagnosed with lung cancer from 2014 to 2016 were selected and divided into three groups: the observation group treated with the combination of Shen Qiu pollen tablets and the chemotherapy group, and the control group treated with chemotherapy alone. Follow-up to collect the patient’s efficacy and prognosis information, the main analysis of this study discussed the follow-up of 3 months of short-term prognosis, and comparative discussion. Statistical analysis using SPSS 16.0 statistical package. Results The complete remission rate of observation group was 3.33% in NSCLC patients, and there was no complete remission in control group. Compared with control group, the proportion of stable cases in observation group was higher than that in control group, and the proportion of progress cases in observation group was significantly lower than that in control group Group, P <0.01; in addition, the total efficiency of both groups also prompted the observation group was higher than the control group P <0.01. Small-cell lung cancer patients in the observation group and control group were followed up for 3 months and non-small cell lung cancer patients with similar efficacy. The results of prognosis analysis in NSCLC patients showed that the quality of life in the observation group was 59.09%, higher than that in the control group (45.45%, P <0.05), and the quality of life reduced in the observation group was lower than that in the control group The recurrence rate at 3 months was 4.55%, significantly lower than that in the control group (P <0.01). In patients with small cell lung cancer, the quality of life in the observation group was significantly higher than that in the control group (P <0.01), but the percentage of stable patients was lower than that in the control group (P <0.05). The follow-up rate of 3 months in the observation group was 12.50%, which was significantly lower than that in the control group (P <0.05). Conclusion The combination of shenqi pollen tablets and chemotherapy for short-term prognosis in NSCLC and small cell lung cancer patients have played a good quality of life improvement, especially for patients with NSCLC is more obvious; the addition of shenqi pollen tablets combined with chemotherapy can to a certain extent, reduce NSCLC Patient relapse rate and metastatic rate in patients with small cell lung cancer.